galcanezumab-gnlm

galcanezumab-gnlm (EMGALITY) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

EMGALITY is a marketed brand name for galcanezumab-gnlm. Check FDA Drugs@FDA for the current US label holder and prescribing information.

galcanezumab-gnlm has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.